Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma

Background: The purpose of this systematic review is to summarize and evaluate the available published data regarding the efficacy and safety of a combination product containing fluticasone propionate/formoterol (FP-F) in order to establish its potential role compared with other inhaled combination corticosteroid/long-acting beta receptor agonists for the maintenance treatment of asthma.

Methods: A PubMed and EMBASE search was conducted using the terms “fluticasone propionate”, “formoterol fumarate”, “Flutiform,” and “asthma” in July 2014 to identify trials using this combination specifically for the treatment of asthma. Additional information was gathered from references cited in the identified publications, the package insert, and the ClinicalTrials.gov registry. All randomized controlled clinical trials for humans in asthma were evaluated for inclusion. Data from animal trials, clinical trials for chronic obstructive pulmonary disease, and non-English sources were excluded.

Results: Seven short-term safety and efficacy trials of FP-F compared with its individual components and two comparison trials of FP-F versus other combination products were identified. Generally, the incidence of drug-related adverse events was low and consistent with previously reported drug class-related adverse events (ie, pharyngitis, dysphonia, and headache). The combination of FP-F was shown to be noninferior to fluticasone propionate/salmeterol for improving predose forced expiratory volume at one second (FEV1) and 2 hours post dose FEV1. FP-F was also noninferior to budesonide/formoterol in improving predose FEV1. Other clinical endpoints, including various symptom scores, asthma control, quality of life, and subjects’ assessment of the medications were not significantly different.

Conclusion: Poor asthma control is common. The data from short-term studies indicate that this inhaled corticosteroid and long-acting beta receptor agonist combination product is noninferior to similar combination products available. As FP-F is available in different strengths, the corticosteroid dose can be titrated without changing devices. A potential advantage is that those with good technique, the same type of device could be used for both their controller and rapid relief inhaler medicines. The choice of this combination versus other similar products may be based primarily on cost.

Keywords: fluticasone-formoterol, asthma, inhaled corticosteroids, long-acting beta receptor agonists, Flutiform®

Challenges to optimally controlling and managing asthma

Asthma is a world-wide problem affecting an estimated 300 million people. The prevalence of asthma varies widely throughout the world from less than 2% in some countries (eg, Greece and the People’s Republic of China) to over 10% in others (Australia, Vietnam, UK, USA). Part of the variation in prevalence could be due to the lack of uniform criteria for diagnosing asthma. The prevalence of asthma is increasing in many areas, including Africa, Latin America, Eastern Europe, Asia, and the USA.
For example, the prevalence of asthma increased in the USA by 14.8% in less than 10 years (2001–2010).²

Asthma is a major health issue worldwide not only because of its prevalence, but also its impact on morbidity and mortality. The World Health Organization estimates 13.8 billion disability-adjusted life years each year related to asthma.³ Approximately 346,000 deaths worldwide are attributable to asthma annually.³ The economic impact of asthma is quite large, including both direct costs, eg, medication and routine and urgent care, and indirect costs, eg, decreased quality of life and productivity, and missed school/work days.¹

Adequacy of asthma control is assessed by a combination of symptom frequency and risk for future poor asthma outcomes.⁴ Control of symptoms is defined by a frequency of daytime symptoms and rapid reliever use of less than twice weekly and an absence of night-time symptoms and activity limitations.⁴ Risk for poor outcomes includes excessive rapid reliever use (ie, more than 200 doses/month), poor controller adherence (often defined as taking less than 80% of prescribed doses per month), incorrect device technique, and decreased lung function, eg, forced expiratory volume at one second (FEV₁) less than 80% of predicted or personal best.

Both the Global Initiative for Asthma⁴ and National Asthma Education and Prevention¹ guidelines recommend inhaled corticosteroids (ICS) as first-line long-term controller therapy for persistent asthma to decrease airway inflammation. For persistent asthma not controlled by low-dose ICS therapy alone, adding a long-acting β₂ receptor agonist (LABA) can be an alternative to increasing to a moderate dose of the ICS. Combining an ICS and a LABA into a single device increases patient convenience and potentially adherence. There is little benefit to further increases in the dose of LABAs because the dose-bronchodilation response curve is fairly flat;³ that is, further increases in dose result in minimal incremental bronchodilation. Therefore, the dose of LABAs in these combination products is often constant; a further step-up in therapy is usually accomplished by additional increases in the dosage of the ICS component (see examples of such combination products in Table 1 and a comparison of ICS doses in Table 2). In addition to a controller medication, patients are usually prescribed an inhaled short-acting β₂ receptor agonist to use as needed for rapid relief of symptoms.³,⁴

Asthma can often be controlled with appropriate medications, but poorly controlled asthma is still quite common. Reasons for poor control vary by patient and are likely multifactorial, including chronic exposure to triggers, lack of asthma action plans to deal with acute symptoms, poor perception by patients of symptoms that indicate poor control, and poor adherence.⁶ Nonadherence with daily controller medications is very common, and increases the risk of poor outcomes and results in additional health care costs. In a review of ten studies, the mean adherence rate with controller medications was only 48%.⁶ An analysis of electronic prescription and filled claims data revealed that almost one-quarter of first-time prescriptions for controller medications were never picked up or started (ie, primary nonadherence).⁸ More than 50% of US adults in one large study did not refill a

### Table 1 Examples of ICS-LABA combination products and devices⁴

<table>
<thead>
<tr>
<th>Drug (brand name)</th>
<th>Type of device</th>
<th>Strength(s) µg ICS/LABA</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEC-F</td>
<td>MDI</td>
<td>100/6</td>
</tr>
<tr>
<td>BUD-F (Symbicort)</td>
<td>DPI (Turbuhaler)</td>
<td>100/6 200/6 400/12</td>
</tr>
<tr>
<td>FF-V (Breo)</td>
<td>DPI (Ellipta)</td>
<td>100/25</td>
</tr>
<tr>
<td>FP-S (Advair, Seretide)</td>
<td>DPI (Diskus)</td>
<td>100/50 250/50 500/50</td>
</tr>
<tr>
<td>FP-F (Flutiform)</td>
<td>HFA-MDI</td>
<td>50/5 125/5 250/10</td>
</tr>
<tr>
<td>MM-F (Dulera)</td>
<td>HFA-MDI</td>
<td>100/5 200/5</td>
</tr>
</tbody>
</table>

**Note:** Product availability and strengths may vary by country.

**Abbreviations:** BEC, beclomethasone; BUD, budesonide; DPI, dry powder inhaler; F, formoterol; FF, fluticasone furoate; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β₂ receptor agonist; MM, mometasone; HFA MDI, hydrofluoroalkane metered-dose inhaler; S, salmeterol; V, vilanterol.

### Table 2 Comparison of ICS doses in adults and children 12 years and older³

<table>
<thead>
<tr>
<th>ICS</th>
<th>Total dose (µg) per day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>200–500</td>
</tr>
<tr>
<td>Beclomethasone</td>
<td>100–200</td>
</tr>
<tr>
<td>Budesonide</td>
<td>200–400</td>
</tr>
<tr>
<td>Ciclesonide</td>
<td>80–160</td>
</tr>
<tr>
<td>Flunisolide</td>
<td>320</td>
</tr>
<tr>
<td>Fluticasone propionate DPI</td>
<td>100–200</td>
</tr>
<tr>
<td>Fluticasone propionate HFA</td>
<td>100–200</td>
</tr>
<tr>
<td>Mometasone furoate</td>
<td>110–220</td>
</tr>
<tr>
<td>Triamcinolone acetonide</td>
<td>400–1,000</td>
</tr>
</tbody>
</table>


**Abbreviations:** ICS, inhaled corticosteroids; HFA, hydrofluoroalkane inhaler; DPI, dry powder inhaler.
controller medicine within 12 months of the initial prescription (ie, secondary nonadherence). In other studies, a third to half of patients who continue controller medicines either underused them or did not use them as prescribed. Patients most likely to be adherent are: males older than 35 years and those with comorbidities, moderate to severe asthma, and a low copayment. The lack of generic products for asthma controller medications generally increases the patients’ cost of these agents and may decrease adherence.

Unfortunately, undertreatment of asthma by providers is significant and also contributes to poor asthma control. In one study, only 55% of children with persistent asthma were taking a controller medicine. In part, undertreatment is related to an underestimation of symptoms by both patients and providers. Poor device technique limits drug delivery to the lungs and lowers efficacy. In studies, 28%–68% of subjects have been reported to not use a metered-dose or dry powder inhaler well enough for the medication to be effective.

The United States Healthy People 2020 Initiative includes goals to improve asthma outcomes and reduce asthma-related urgent care visits and deaths by increasing the proportion of patients on therapy consistent with asthma guidelines, having written asthma action plans, and receiving formal patient education. Other ways to potentially improve asthma control would be to improve adherence to medications and device technique.

Asthma impacts patients’ quality of life and this effect should be assessed periodically. Quality of life for children with asthma has been defined as the measure of emotions, asthma severity, symptoms, urgent care visits, missed school days, and degree of activity limitation. Various quality of life questionnaires are recommended as part of routine assessment of asthma control. Symptom scores are another method for assessing daily disease impact.

Combination of fluticasone propionate-formoterol fumarate

A relatively new fixed-dose product combines an ICS, fluticasone propionate (FP), with formoterol fumarate (F), a LABA. Both of these medications have been previously available individually and in combination with other medications (Table 1). This new combination is available in 18 European countries under the name Flutiform® in a pressurized metered-dose inhaler with a hydrofluoroalkane (HFA) propellant. It contains 120 actuations, and is indicated for patients aged 12 years and older with persistent asthma. This combination (FP–F) is also available (via multiple marketing partners by the manufacturer) in Australia, Hong Kong, Israel, South Korea, and Japan. This systematic review examines the clinical efficacy trials of the FP–F combination, and summarizes the general pharmacologic properties and safety data for the individual components. This information is then integrated to evaluate the potential role of the FP–F combination in the treatment of asthma.

Pharmacology of fluticasone propionate and formoterol fumarate

Formoterol provides 12 hours of bronchodilation, so it is classified as a LABA. The duration of action of formoterol is comparable with that of salmeterol; both are used as asthma controller medications in combination with an ICS. The duration of formoterol is longer than that of albuterol, which is usually used as a rapid reliever medication. It is hypothesized that its prolonged duration of action is due to the lipophilic and basic properties of formoterol, which favor formation of a drug depot in the lipid bilayers of airway smooth muscle. Throughout the dosage interval, formoterol leaches out from the depot to interact with the beta receptor. In contrast, salmeterol has a lipophilic “tail” that attaches to an exo-site, allowing the drug’s “head” to remain close as it engages and disengages from the beta receptor. Salmeterol’s slower diffusion to the beta receptor site is thought to be responsible for its longer onset of action (more than 30 minutes) compared with formoterol (10 minutes) and albuterol (within minutes). It is thought that the N-aralkyl group on formoterol is responsible for the strong beta receptor selectivity and the formamide group for its intrinsic activity and affinity for the beta receptor. Formoterol is more potent than salmeterol; equipotent doses are thought to be 12 µg to 50 µg, respectively. In addition, formoterol is a full beta2 receptor agonist, while salmeterol and albuterol are partial agonists. This activity at the receptor may explain the smaller maximal effect of salmeterol compared with formoterol. It is not clear if these pharmacologic differences translate into differences in clinical efficacy. As a class, LABAs are usually well tolerated, but have been reported to cause sinus congestion, rhinitis, headache, and influenza.

Corticosteroids modulate gene expression to decrease the production and release of cytokines and other mediators causing airway inflammation. Corticosteroids also decrease the recruitment of eosinophils to the airways, which further decreases mediator release and inflammation. While mast cell stabilizers and leukotriene modifiers can also be asthma controller medications, ICS are the preferred long-term controller medication. Usually, ICS are well
tolerated. The most common adverse reactions are local oral candidiasis, dysphonia, upper respiratory infections, and throat irritation.15 These can be minimized or avoided by using the lowest possible dose,16 administering by a holding chamber (with metered-dose inhalers), and rinsing the mouth after use.4,17 Using the lowest effective dose of ICS limits long-term drug exposure, thereby minimizing the potential for systemic effects (eg, slower linear growth, decreases in bone mineral density, increase frequency of cataracts or glaucoma).18 FP has properties typical of other ICS agents. The estimated comparisons of “low”, “medium”, and “high” doses of different ICS (Table 2) are to guide the clinician in titrating the minimal effective dose to achieve and maintain asthma control. The treatment algorithms for adults and children are similar. However, the ICS dose “cut points” for children are slightly lower than for adults. For example, a “low” dose of FP in children younger than 5 years of age is less than 100 µg whereas a “low” dose in adults is less than 250 µg.1

Data sources
An initial PubMed and EMBASE search was conducted in July 2014 for clinical trials using the following terms: “fluticasone propionate”, “formoterol fumarate”, “Flutiform®”, and “asthma”, with no time limits. Clinicaltrials.gov was searched utilizing the terms “fluticasone propionate” and “formoterol fumarate”. Additional publications were identified by reviewing the references of the included trials and the drug monograph. In evaluating data for inclusion, priority was given to blinded, randomized, controlled studies evaluating efficacy and/or safety. In vitro studies and non-English publications were excluded, as were trials involving animals or subjects with chronic obstructive pulmonary disease. Due to the small number, all identified clinical studies were included. These were all published between 2011 and 2013.

Safety and efficacy trials
The safety and efficacy of the FP-F combination has been assessed in seven trials.19–24 Two of the trials20,22 have been summarized in a previous review.23 All of these trials assessed subjects who were at least 12 years of age and older. Table 3 summarizes the methodology and results of these trials. Two trials19,22 were placebo-controlled, five trials19,20,22,24 compared the combination inhaler with its individual components (ie, FP and/or F alone), and two trials21,26 compared the combination inhaler with FP plus F administered in two separate devices. All of these19–24 were brief, lasting 8–12 weeks. All had similar inclusion criteria documenting subjects with mild to moderate asthma. The primary efficacy endpoints were change in predose and/or 2 hours post dose FEV1. The combination inhaler product was found to improve FEV1 to a greater extent than placebo,19,22 and the individual components19,20,22–24 were noninferior to combination therapy administered by separate devices.20,21 Other endpoints included: rescue medication use, asthma symptom scores, asthma-control days, symptom-free or rescue medication-free days, sleep disturbances, and awakening-free nights. There were some isolated differences across the studies. In one study,19 rescue medicine use and frequency of exacerbations were lower; there were more symptom-free days in the combination group versus placebo. In another,20 there were fewer subjects discontinuing therapy in the combination group than with fluticasone alone. In a third study,22 there were more rescue-free and symptom-free days versus fluticasone alone. Often however, the differences between the groups for these clinical outcomes were not significant. Across these studies, the adverse effects reported were mild to moderate. The most common adverse effects were nasopharyngitis, pharyngitis, headache, asthma exacerbations, and dysphonia. No laboratory, blood pressure, electrocardiogram, or heart rate abnormalities were reported.

The strengths of these studies were the documentation of asthma by pulmonary function tests prior to study entry and objective exclusion of those with chronic obstructive pulmonary disease, recent exacerbations, or severe asthma. Adherence was generally good (ie, greater than 75% of doses) assessed by diary or dose counters.19,21–23 Device instruction was given and/or device technique assessed prior to study entry.19–21 For studies using more than one dose of the ICS, the study ICS dose for an individual subject was determined based on the prestudy ICS dose of the subject. The general lack of differences in clinical endpoints between studies might be explained by varying levels of asthma severity, relatively short duration of the trials, and lack of sufficient numbers of subjects for adequate power to detect differences in secondary endpoints. Overall, the combination of FP-F improved pulmonary function when compared to its individual components and placebo, and was well tolerated.

One open-label trial25 involving 465 subjects evaluated the tolerability of the FP-F combination product (either 100/10 or 250/10 µg) for a longer period (6–12 months). The incidence of drug-related adverse events was low at only 3.8%, and none were considered serious. The most frequent adverse events (>2%) were nasopharyngitis, dysphonia,
Table 3: Summary of safety and efficacy trials of fluticasone-formoterol

<table>
<thead>
<tr>
<th>References</th>
<th>Methods</th>
<th>Pulmonary function results primary endpoints</th>
<th>Clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corren et al19</td>
<td>Design: R, DB, C, Subjects: n=556 over 12 years (395 completed) Location: North America, Europe Duration: 12 weeks Intervention: (twice daily) FP-F 250/10 µg FP-F 100/10 µg FP 250 µg F 10 µg Placebo</td>
<td>Mean change in FEV, from predose baseline: FP-F 250/10 better over F alone (189 mL; P=0.001) Mean change in FEV, predose baseline to 2 hours post dose better over FP alone (146 mL; P=0.006)</td>
<td>Rescue medication use: FP-F 250/10 better than placebo only (95% CI -1.85, -0.74) for inhalations/day Symptom scores: 0 none; 5 severe (95% CI -0.592, -0.237; P&lt;0.001) for placebo only Symptom-free days: NS Rescue-medicine free days: NS Percent asthma control days: NS Frequency of exacerbations FP-F 250/10 had fewer (any level of severity) exacerbations than placebo only (95% CI 1.88–6.12; P&lt;0.001) AQLQ: NS Awakening-free nights: NS</td>
</tr>
<tr>
<td>Bodzenta-Lukaszyk et al20</td>
<td>Design: R, DB, double dummy; noninferior Subjects: n=620 over 18 years (540 completed) Location: Europe, India, Israel Duration: 8 weeks Intervention: twice daily FP-F 500/20 µg FP-F 100/10 µg FP 500 µg F 24 µg* FP 500 µg</td>
<td>Mean change in pre-morning dose FEV, FP-F 500/20 (345 mL) at least as effective as FP + F (284 mL; P&lt;0.001) Mean change in pre-morning to 2 hours post dose FEV, FP-F 500/20 (518 mL) at least as effective as FP + F (500 mL; P&lt;0.001); superior to FP alone (396 mL)</td>
<td>Discontinuations due to lack of efficacy: FP-F 500/20 superior to FP, noninferior to FP + F Symptom-free days: FP-F superior (P&lt;0.05) to FP Subjects’ assessment of study medication: FP-F superior (P&lt;0.05) to FP AQLQ: FP-F superior (P&lt;0.05) to FP</td>
</tr>
<tr>
<td>Bodzenta-Lukaszyk et al21</td>
<td>Design: R, open-label, active control, parallel groups; noninferior Subjects: n=210 over 12 years (197 completed) Location: Five European countries Duration: 12 weeks Intervention: twice daily FP-F 100/10 µg FP-F 250/10 µg FP 100/ F 24 µg* FP 250/ F 24 µg*</td>
<td>Mean post dose FEV, FP-F noninferior to FP + F (P=0.004) Change in predose to post dose FEV, FP-F noninferior to FP + F (P=0.004)</td>
<td>Discontinuation: FP + F noninferior Severe exacerbations: NS Symptom scores: NS Sleep disturbance: NS Patient assessment: NS AQLQ: NS Rescue medicine use: NS</td>
</tr>
<tr>
<td>Nathan et al22</td>
<td>Design: DB, R, P, and active-control, parallel Subjects: n=475 over 12 years (367 completed) Location: Europe, North America Duration: 12 weeks Intervention: twice daily FP-F 100/10 µg FP 100 µg F 10 µg Placebo</td>
<td>Mean change in predose FEV, FP-F superior (195 mL) to FP (92 mL; P=0.04), F (94 mL; P=0.045), and placebo (47 mL; P=0.004) Mean change in FEV, from predose to 2 hours post dose: FP-F superior (392 mL) to FP (191 mL; P&lt;0.001) and placebo (124 mL; P&lt;0.001), but not F (330 mL; P=0.187)</td>
<td>Exacerbations: NS Rescue medicine-free days: FP-F (56%) improved over FP (43%; P=0.02) and placebo (39%; P=0.012), but not F (42%; P=0.125) Control days: NS Symptom-free days: FP-F over FP only (P=0.27) Awakening-free nights: NS</td>
</tr>
</tbody>
</table>

(Continued)
### Table 3 (Continued)

<table>
<thead>
<tr>
<th>References</th>
<th>Methods</th>
<th>Pulmonary function results (primary endpoints)</th>
<th>Clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertseva et al</td>
<td>Design: DB, R, active-control, parallel</td>
<td>Mean change in predose FEV₁, to 2 hours post-dose</td>
<td>• Asthma symptoms scores: NS</td>
</tr>
<tr>
<td></td>
<td>Subjects: n=38 over 12 years (392 completed)</td>
<td>F-P-F LSM difference 161 mL versus SkyPharma FP (95% CI 78–245; P&lt;0.001) and GSK FP 185 mL (95% CI 102–268; P&lt;0.001)</td>
<td>• Sleep disturbance scores: NS</td>
</tr>
<tr>
<td></td>
<td>Location: Europe, South America, USA</td>
<td></td>
<td>• Rescue medicine use: NS</td>
</tr>
<tr>
<td></td>
<td>Duration: 12 weeks</td>
<td></td>
<td>• Asthma-control days: NS</td>
</tr>
<tr>
<td></td>
<td>Intervention: twice daily</td>
<td></td>
<td>• Percent subjects with exacerbations: NS</td>
</tr>
<tr>
<td></td>
<td>• F-P-F 250/10 μg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• FP 250 μg (GSK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• FP 250 μg (SkyPharma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pearlman et al</td>
<td>Methods: R, DB, active control, parallel</td>
<td>Predose FEV₁, LSM change 118 mL (95% CI 34–201; P=0.006) versus F</td>
<td>• Rescue medicine-free days: NS</td>
</tr>
<tr>
<td></td>
<td>Subjects: n=357 over 12 years (269 completed)</td>
<td>Predose to 2 hour post dose FEV₁, LSM change 122 mL (95% CI 40–204; P=0.004) versus FP</td>
<td>• Asthma control days: NS</td>
</tr>
<tr>
<td></td>
<td>Location: USA, Canada</td>
<td></td>
<td>• Awakening-free nights: NS</td>
</tr>
<tr>
<td></td>
<td>Duration: 12 weeks</td>
<td></td>
<td>• Use of rescue medicine: NS</td>
</tr>
<tr>
<td></td>
<td>Intervention: twice daily</td>
<td></td>
<td>• Asthma symptom scores: NS</td>
</tr>
<tr>
<td></td>
<td>• F-P-F 100/10 μg</td>
<td></td>
<td>• Exacerbations: NS</td>
</tr>
<tr>
<td></td>
<td>• FP 100 μg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• F 10 μg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Fluticasone propionate and formoterol were administered in two separate inhaler devices.

Abbreviations: AQLQ, Asthma Quality of Life Questionnaire; C, controlled; DB, double-blind; F, formoterol; FEV₁, forced vital capacity at one second; FP, fluticasone propionate; FP-F, fluticasone propionate-formoterol; NS, non significant; LSM, least squared mean; R, randomized; CI, confidence interval.

### Comparison trials of fluticasone-propionate-salmeterol (FP-S) in adult patients with moderately severe asthma

Comparison trials of fluticasone-propionate-formoterol (FP-F) versus other ICS-LABA combinations

The results supported FP-F noninferior to FP-S for the primary endpoint of predose FEV₁ at week 12. There were no differences noted in clinical endpoints such as symptom scores, sleep scores, and use of rescue medicine. The number of subjects discontinuing due to lack of effect, amount of rescue or systemic corticosteroids used, frequency of adverse events, and quality of life scores. Researchers calculated the percentage of adherence by dividing the number of actuations taken by number of actuations that should have been taken.

The strengths of this study were the well-defined criteria for exclusion of subjects with chronic obstructive pulmonary disease, no significant changes in serum glucose or potassium. The results with fluticasone propionate-salmeterol (FP-S) in adult patients with moderately severe asthma. After a screening phase, subjects were randomized to receive either FP-F or FP-S. After the 12-week study, the ICS dose was increased for both groups to determine the ICS dose prior to study entry, but those starting at the lower ICS dose could be switched to a higher dose during the study. Subjects were randomized to receive one of the study medicines. The primary objective was the comparison of mean predose FEV₁ at week 12. Secondary objectives were to compare the time to onset and frequency of discontinuation due to lack of effect, amount of rescue or systemic corticosteroids used, and quality of life scores. Researchers calculated the percentage of adherence by dividing the number of actuations taken by number of actuations that should have been taken.

No significant differences in laboratory values or vital signs were reported.
Asthma symptoms scores (0, no symptoms; 5, severe): LSM difference

Results

2

AQLQ scores: mean improvement 0.8 in both groups (95% CI

Time to onset: favored FP-F; HR 1.64 (95% CI 1.28, 2.10); P<0.001

Sleep disturbances LSM 0.00 (95% CI

1

Discontinuation due to lack of efficacy: LSM difference

Percent asthma symptom-free days (ie, symptom score 0) LSM difference

Study design

Mean change in predose FEV

Baseline ICS therapy

Arm 1

100–250 µg/day

FP-F 100/10 µg
twice daily

FP-S 100/25 µg
twice daily

250–1,000 µg/day

FP-F 250/10 µg
twice daily

FP-S 250/50 µg
twice daily

Arm 2

(F equivalent)

Bodzenta-Lukaszyk et al27

Design: 12-week, R, DB, double placebo, parallel-group, Phase III, noninferiority

Location: Europe and India

Objective: Compare efficacy and safety of FP-F HFA inhaler 250/10 µg or BF Turbuhaler® DPI 400/12 µg twice daily

Subjects: 279 (140 FP-F, 139 BF); older than 12 years (average 49 years) with moderately to severely persistent asthma for >6 months

Inclusion:

• Baseline treatment with ICS 250–1,000 µg daily (FP equivalent) OR with ICS-LABA combination 200–500 µg (F equivalent)

• FEV

50%–80% predicted

Bodzenta-Lukaszyk et al39

Design: 12-week, R, DB, double placebo, parallel-group, Phase III, noninferiority

Location: Europe

Objective: Compare efficacy and safety of FP-F with FP-S

Subjects: 202 adults (average age 47 years) with mild to moderately severe persistent asthma for >6 months

Inclusion:

• PFTs, FEV

≥40% and ≤85% of predicted values with at least 15% change after BA

• Demonstration of correct HFA inhaler technique with Aerocam®h holder

Intervention: 12 weeks

Table 4 Studies comparing fluticasone-formoterol with another inhaled corticosteroid/long-acting beta agonist combination

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Results</th>
</tr>
</thead>
</table>
| Bodzenta-Lukaszyk et al27 | Methods: open-label, RC, parallel-group, Phase III, noninferiority | Primary objective: Treatment difference in predose FEV

LSM was −61 mL (95% CI −0.161, 0.040); P=0.007 (noninferiority)

Secondary outcomes:

• Discontinuation due to lack of efficacy: LSM difference −1.1% (95% CI −4.6, 2.5); noninferiority

• Time to onset: favored FP-F; HR 1.64 (95% CI 1.28, 2.10); P<0.001

• Percentage of subjects assessing the medicine as good/very good: 84% FP-F and 91% FP-S (OR 0.495, 95% CI 0.289–0.848)

• Percent days with rescue medicine use: LSM 2.24 (95% CI −0.03, 7.06; P=0.157)

• Asthma symptoms: LSM 0.15 (95% CI −0.04, 0.34; P=0.122)

• Sleep disturbances LSM 0.00 (95% CI −0.12, 0.11; P=0.975)

• AQLQ (32 questions; 7=no impairment, 1=severely impaired): mean 5.4 (FP-F) and 5.5 (FP-S); P=0.051

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Results</th>
</tr>
</thead>
</table>
| Bodzenta-Lukaszyk et al39 | Design: 12-week, R, DB, double placebo, parallel-group, Phase III, noninferiority | Primary endpoint: Mean change in predose FEV

(FP-F minus BF) = −0.44 (95% CI −0.130, 0.043; P<0.001), noninferiority

Secondary outcomes:

• Predose FEV

1 to 2 hours post dose adjusted mean change 319 mL (FP-F) and 406 mL (BF). LSM difference −0.087 L (95% CI −0.173, −0.001; P=0.010), noninferiority

• Discontinuations due to lack of efficacy 3.1% (95% CI −1.3, 7.5)

• Asthma symptoms scores (0, no symptoms; 5, severe): LSM difference −0.01 (95% CI −0.13, 0.12; P=0.904)

• Percent asthma symptom-free days (ie, symptom score 0) LSM difference −0.54 (95% CI −8.36, 7.27; P=0.891)

• Sleep disturbance scores (ie, 0, slept through the night; 4, no sleep): LSM difference 0.03 (95% CI −0.04, 0.11; P=0.37)

• Awakening-free nights: LSM difference −5.08 (95% CI −11.15, 0.99; P=0.101)

• Percent asthma control days (symptom and sleep disturbance score 0 without rescue medicine): LSM difference −2.27 (95% CI −10.29, 5.75)

• Severe asthma exacerbations (ie, requiring systemic corticosteroids) L FP-F, 2 BF (P=0.6223)

• Percent rescue medicine-free days: LSM difference 2.58 (95% CI −5.09, 10.25; P=0.508)

• Subjects’ assessment of study medicine as “good” or “very good”: 90% FP-F versus 88% BF

• AQLQ scores: mean improvement 0.8 in both groups (95% CI −0.1, 0.2; P=0.630)

Abbreviations: AQLQ, Asthma Quality of Life Questionnaire; BA, beta agonist; BF, budesonide plus formoterol; C, controlled; CI, confidence interval; DB, double-blind; FP, fluticasone propionate; FEV

forced vital capacity at one second; FP-F, fluticasone propionate plus formoterol; FP-S, fluticasone propionate plus salmeterol; HFA, hydrofluoroalkane inhaler; HR, hazard ratio; ICS, inhaled corticosteroids; LABA, long-acting beta receptor agonist; LSM, least squared mean; OR, odds ratio; PFTs, pulmonary function tests; R, randomized.
disease and confounding tobacco use. Subjects were stratified by prior dose of ICS. The use of HFA inhalers with a holding chamber for both study medicines and provision of device technique instruction controlled for potential differences in devices and device technique. The researchers clearly defined endpoints, such as criteria for exacerbations and included other clinical efficacy outcomes. Adherence (taking more than 75% of doses) was high in both groups (98% and 99% of subjects). Limitations included the short duration of the study. Also, more men were included in the FP-F arm than the FP-S arm (47% versus 39%) and the average of the prior fluticasone equivalent dose was also higher in the FP-F group (500 µg versus 400 µg per day). A couple of factors could affect external validity of this study. All subjects were of Caucasian race, and others, such as Asian or black patients, could respond differently. Over 70% of subjects in both groups were started on the higher dose of ICS. It is possible that there could be differences between these medicines when lower ICS doses are used.

Subsequently, the researchers performed a post hoc analysis of these data to further evaluate differences in speed of onset between FP-F and FP-S. The odds ratio (OR) of achieving bronchodilation within 5 minutes of a dose were higher in the FP-F group both on day 0 (OR 3.97; 95% confidence interval [CI] 1.96–8.03) and day 84 (OR 9.58; 95% CI 2.14–42.9). Those in the FP-F group were more likely to have an onset of bronchodilation within 120 minutes on day 0 (hazard ratio 1.47; 95% CI 1.05–2.73) and also on day 84 (hazard ratio 1.77; 95% CI 1.14–2.73). The least square mean change in FEV₁ from predose on day 0 favored FP-F (0.112 L; 95% CI 0.42–0.181; P=0.002) and day 84 (0.06 L; 95% CI 0.008–0.113). The authors postulate that these data could translate into improved treatment adherence in patients with asthma. However, this interpretation should be accepted cautiously; the overall difference in FEV₁ was relatively small and may not translate into a detectable improvement of clinical symptoms. Also, in the original study, slightly more subjects assessed FP-S as good or very good despite this reported difference in onset.

Only one other ICS-LABA comparison study was found. A FP-F HFA inhaler (250/10 µg twice daily) was compared with budesonide-formoterol (B-F, 400/12 µg twice daily) administered by a dry powder device (Turbuhaler®). Subjects at least 12 years of age and older with uncontrolled asthma on 200 µg daily of fluticasone at the end of a 14-day run-in period were randomized. Up to eight inhalations of albuterol were allowed daily as rescue medicine. Subjects were stratified into each treatment group based on their degree of lung impairment (FEV₁ over 60% predicted and 50%–60% predicted). All but ten subjects (six FP-F and four B-F) were taking ICS at study entry (mean dose 500 µg FP equivalents) with a mean predicted FEV₁ of 66%.

Results support FP-F as being comparable with B-F in terms of the primary endpoint (change in predose FEV₁) and secondary endpoints including symptom and sleep disturbance scores, percentage of symptom-free days, asthma control days, awakening-free nights, quality of life scores, and subjects’ assessment of the medicine (Table 4). Of the 18 subjects discontinuing the study, only eight were due to lack of efficacy (six B-F and two FP-F). There were no changes in serum potassium or glucose, vital signs, or electrocardiograms. The researchers concluded that the effect of FP-F on lung function and other efficacy monitors was comparable with B-F.

The strengths of the study were clear entry criteria for asthma and level of severity. Demonstration of good device technique was required for entry. Those with tobacco use and severe or uncontrolled asthma in the last 4 weeks were excluded. The doses of budesonide and fluticasone were comparable. Adherence was measured (based on the number of actuations recorded in an electronic diary), and 96% of subjects recorded taking 75% or more of doses. Criteria for endpoints such as worsening asthma and subject withdrawals were well defined. Many clinical endpoints were evaluated, providing a more robust support for the conclusion of noninferiority.

A limitation was the use of different devices to deliver the study medications. The devices used were based on the availability of the medicine in the countries where the study was conducted. However, checking device technique of subjects prior to study entry limits the impact of this variable. It should be noted that the B-F dry powder inhaler used in this study is not available in some countries (eg, the USA). There was also a slightly higher dose of formoterol in the B-F arm. However, due to the relatively flat dose-response curve of LABA agents, that would not be likely to significantly affect the results. More women were randomized to the B-F group (72.7% B-F to 62.9% FP-F). However, the authors noted the post hoc exploratory analysis did not reveal any significant sex differences in the primary outcome. These factors might have been more significant if a difference in outcomes between the study medicines had been noted.

**Discussion**

Flutiform® is a relatively new ICS-LABA (FP-F) combination product in the asthma market. Use of a LABA-ICS
combination is appropriate for patients whose asthma cannot be managed with low-dose ICS monotherapy. Recent reports of serious asthma exacerbations and asthma-related deaths have raised concerns regarding the use of LABAs (especially as single-drug controller therapy). On the other hand, the results of a recent meta-analysis indicate that stepping down treatment from an ICS-LABA combination to an ICS alone resulted in increased asthma impairment, worsening of asthma quality of life questionnaire scores, and fewer symptom-free days. It is useful to prescribe a combination ICS-LABA inhaler for those requiring both medications. A combination product minimizes the risk of nonadherence to one inhaler and resulting inadvertent monotherapy with either an ICS or LABA alone.

For patients requiring combination therapy, there are several considerations in selecting the best product. The first and foremost consideration is usually efficacy. At this time, there are no data to suggest that one ICS-LABA combination product is better than another if comparable doses are used. The FP-F combination product is available in three strengths, ie, 50/5 µg, 125/5 µg for those aged 12 years and older, and 250/10 µg for those aged 18 years and older. By having multiple strengths available, clinicians may more easily titrate the ICS dose without having to switch to another combination product and potentially switch to another device. This is not an option for all combination products. For example, budesonide/formoterol HFA is only available in two strengths, making it difficult to titrate to a high-dose ICS without going over the usual recommended daily dose of the LABA.

The second consideration in selection of medication is often differences in potential or actual adverse reactions. At this time, there do not appear to be any significant differences in the common adverse reactions between the currently available combination products. In the rare circumstance of a patient with a history of severe milk protein allergy, the FP-F combination product (Flutiform®) or budesonide/formoterol would be preferred because these products currently do not contain lactose. However, clinicians should double-check the most current product information before prescribing in case the product formulation has changed.

With little difference in efficacy or safety, the third consideration is cost. Flutiform® is not yet approved in all major markets (eg, the USA). The pricing in each individual country where it is available likely varies. In general, combination inhaler products are less expensive than the individual agents in separate devices. Patients may also benefit from combination products because of a single copayment versus two copayments (one for each individual product). In choosing between combination products, a lesser acquisition cost could be a deciding factor in institutional formulary decisions.

A fourth important consideration is patient preference for and ability to correctly use the specific drug delivery device. There are significant differences in optimal technique between HFA inhalers and dry powder devices, especially regarding the optimal inhalation rate. Most patients with asthma should be familiar with an HFA inhaler, especially if they already use one for their “rescue” inhaler with a short-acting β2 receptor agonist. Patients with good HFA inhaler technique may prefer to use one of the ICS-LABA HFA inhalers like FP-F (Flutiform®), so they only have to learn to use one device.

For those patients with inadequate technique (especially for timing of actuation to inhalation), there are two options. Use of a holding chamber with the HFA inhaler is often recommended. If patients elect to use a holding chamber, only those holding chambers documented to be compatible with that particular inhaler should be utilized. If patients are unable to correctly use the Flutiform® HFA inhaler, the AeroChamber Plus® holding chamber is recommended. An advantage of dry powder delivery devices is that holding chambers are not required to assist with the timing of actuation for inhalation. Patients’ dry powder technique may be better than that with HFA inhalers, but poor device technique is still common with the dry powder devices.

Guidelines from the American College of Chest Physicians indicate that potential device-specific differences in drug delivery are less likely to impact efficacy than the correct use of the specific device prescribed. The recommendation therefore is to select an ICS-LABA product in a device that a particular patient can utilize correctly to optimize drug delivery. Regardless of the product initially chosen, patients should be instructed, periodically reassessed on their device technique, and the results documented in the medical record.

It is useful to have available on formulary products with more than one approved indication as well as products that have been studied in a pediatric population. The manufacturer of FP-F is pursuing a COPD indication in Europe. Product information does not currently include an indication for children younger than 12 years of age. Multiple indications would also add to the versatility of this product.
Conclusion
The use of an ICS/LABA combination is indicated for the maintenance treatment of patients with asthma that cannot be well controlled on low-dose ICS monotherapy. Available data indicate that FP-F therapy in asthma is comparable in efficacy and safety to other combination products for adults. However, no long-term studies or trials in children younger than 12 years of age are available. The potential for better adherence or improved device technique with FP-F should be considered, especially in individual patients who prefer to utilize an HFA inhaler to administer all medications. However, until there are data documenting improved clinical efficacy or safety versus other ICS/LABA combinations, the deciding factor in patient specific and formulary decisions could be cost.

Disclosure
The authors received no funding for this review and report no relevant conflicts of interest.

References


